Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)

April 25, 2023 07:29 AM EDTUpdated 01:18 PM

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Biogen plans to scrap three clinical programs and “deprioritize” preclinical gene therapy and ophthalmology programs as part of CEO Chris Viehbacher’s larger strategy to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

Up­dat­ed: Bio­gen chops cer­tain stroke and RNA ther­a­py pro­grams as it con­tin­ues R&D re­vamp

Senior Reporter

News Reporter

Sign up to read this article for free.

more like this

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp